Pothineni Venkata Raveendra, Wagh Dhananjay, Babar Mustafeez Mujtaba, Inayathullah Mohammed, Solow-Cordero David, Kim Kwang-Min, Samineni Aneesh V, Parekh Mansi B, Tayebi Lobat, Rajadas Jayakumar
Biomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Chemical & Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
Drug Des Devel Ther. 2016 Apr 1;10:1307-22. doi: 10.2147/DDDT.S101486. eCollection 2016.
Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%-20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is no evidence for the presence of viable infectious organisms in individuals with posttreatment Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population in rodents and primates even after antibiotic treatment. Although such observations need more ratification, there is unmet need for developing the therapeutic agents that focus on removing the persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose, high-throughput screening was done using BacTiter-Glo assay for four compound libraries to identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We subsequently identified 150 unique compounds, which inhibited >90% of B. burgdorferi growth at a concentration of <25 µM. These 150 unique compounds comprise many safe antibiotics, chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules based on safety and potency and studied their minimum inhibitory concentration and minimum bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen as lead molecules for further advanced studies.
莱姆病是北美最常见的人畜共患细菌性疾病。据估计,仅在美国每年就报告超过30万例病例。在接受抗生素治疗的患者中,共有10%-20%报告症状复发,如肌肉和关节疼痛、心理社会和认知困难以及全身疲劳。这种情况被称为治疗后莱姆病综合征。虽然没有证据表明治疗后莱姆病综合征患者体内存在活的感染性生物体,但一些研究人员发现,即使在抗生素治疗后,啮齿动物和灵长类动物体内仍有存活的伯氏疏螺旋体种群。尽管这些观察结果需要更多的验证,但开发专注于清除啮齿动物和非人类灵长类动物体内持续存在的伯氏疏螺旋体细菌形式的治疗药物仍存在未满足的需求。为此,使用BacTiter-Glo检测法对四个化合物文库进行了高通量筛选,以鉴定在体外阻止伯氏疏螺旋体生长的候选物。被筛选的包含4366种化合物(80%为美国食品药品监督管理局[FDA]批准)的四个化学文库分别是药理活性化合物文库(LOPAC1280)、美国国立卫生研究院临床收藏文库、Microsource Spectrum文库和Biomol FDA文库。我们随后鉴定出150种独特的化合物,它们在浓度<25µM时可抑制>90%的伯氏疏螺旋体生长。这150种独特的化合物包括许多安全的抗生素、化合物以及来自植物来源的小分子。在这150种独特的化合物中,101种化合物已获FDA批准。我们根据安全性和效力选择了前20种FDA批准的分子,并研究了它们的最低抑菌浓度和最低杀菌浓度。那些显示出低最低抑菌浓度和最低杀菌浓度值的有前景的、安全的FDA批准候选物可被选作进一步深入研究的先导分子。